{
  "platform": "civiq",
  "version": 1,
  "type": "comment-period",
  "data": {
    "documentNumber": "2026-06064",
    "title": "Microbiology Devices; Reclassification of Mycobacterium Tuberculosis Cell-Mediated Immunity Tests and Immune Response Enzyme-Linked Immunospot Tests",
    "summary": "The Food and Drug Administration (FDA) is proposing to reclassify Mycobacterium tuberculosis cell-mediated immunity tests and Mycobacterium tuberculosis cell-mediated immune response enzyme-linked immunospot tests intended for use as an aid in the diagnosis of Mycobacterium tuberculosis infection (product codes NCD and OJN, respectively), both of which are postamendments class III devices (premarket approval), into class II (special controls), subject to premarket notification. FDA is also proposing a new device classification regulation along with the special controls that FDA believes are necessary to provide a reasonable assurance of safety and effectiveness for these devices.",
    "agency": "Health and Human Services Department",
    "commentsCloseOn": "2026-05-29",
    "daysUntilClose": 60,
    "url": "https://www.federalregister.gov/documents/2026/03/30/2026-06064/microbiology-devices-reclassification-of-mycobacterium-tuberculosis-cell-mediated-immunity-tests-and"
  },
  "source": {
    "url": "https://www.federalregister.gov/documents/2026/03/30/2026-06064/microbiology-devices-reclassification-of-mycobacterium-tuberculosis-cell-mediated-immunity-tests-and",
    "api": "federalregister.gov"
  }
}